Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ARMP, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
ARMP reported $24M in cash and short-term investments (as of Jun 30, 2026) and used about $7.3M/quarter in operations, an estimated runway of 9.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 70 · High
These circumstances raise substantial doubt about the Company’s ability to continue as a going concern.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ARMP files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Innoviva, Inc. | 5%+ holder (13D) | 55,467,459 | 149.18% | 2026-05-12 |
| Deborah Birx Chief Executive Officer, Director · +901,226 options |
Insider | 198,417 | 0.53% | 2026-07-10 |
| Richard Rychlik Corporate Controller and PFO · +40,000 options |
Insider | 10,000 | 0.03% | 2024-03-14 |
| Pierre Kyme Chief Business Officer · +283,142 options |
Insider | 9,461 | 0.03% | 2026-03-14 |
Share count 37,181,979 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ARMP and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →